ImdevimabMeSH Supplementary Concept

https://recalls-rappels.canada.ca/fr/avis-rappel/casirivimab-et-imdevimab-risque-eleve-echec-therapeutique-en-raison-circulation-du
2022
false
false
false
Canada
French
English
pharmacovigilance note
COVID-19
casirivimab and imdevimab drug combination
risk
drug combinations
imdevimab
casirivimab
treatment failure
canada
SARS-CoV-2 variants

---
https://www.has-sante.fr/jcms/p_3281625/fr/ronapreve-casirivimab-imdevimab-covid-19
2022
false
false
false
France
French
COVID-19
Post-Exposure prophylaxis
evaluation of the transparency committee
adult
adolescent
aged
risk factors
immunocompromised host
drug combinations
casirivimab and imdevimab drug combination
casirivimab
imdevimab
injections, subcutaneous
infusions, intravenous
antiviral agents
casirivimab and imdevimab

---
https://www.infectiologie.com/fr/actualites/combinaisons-d-ac-monoclonaux-en-traitement-du-sars-cov2_-n.html
2021
false
false
false
France
COVID-19
etesevimab
drug therapy, combination
infusions, intravenous
bamlanivimab
casirivimab
Casirivimab/Imdevimab
treatment outcome
imdevimab
scientific and technical information

---
https://ansm.sante.fr/actualites/covid-19-lacces-aux-bitherapies-danticorps-monoclonaux-contre-la-covid-19-est-elargi
2021
false
false
false
France
French
drug information
drug combinations
antibodies, monoclonal, humanized
adult
Casirivimab/Imdevimab
Bamlanivimab
Etesevimab
guidelines for drug use
casirivimab
imdevimab
bamlanivimab
etesevimab
casirivimab and imdevimab drug combination
COVID-19
casirivimab and imdevimab drug combination
Product containing only casirivimab and imdevimab in parenteral dose form (medicinal product form)

---
Authorization of Casirivimab and Imdevimab with English-only Labels for Use in Relation to the COVID-19 Pandemic
https://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2021/76129a-fra.php
2021
false
false
false
Canada
French
English
drug approval
canada
COVID-19
drug labeling
casirivimab
imdevimab
Casirivimab/Imdevimab
casirivimab and imdevimab drug combination
adult
adolescent
drug combinations
infusions, intravenous
drug information
casirivimab and imdevimab drug combination
coronavirus infections
antibodies, monoclonal, humanized
drug combinations

---
https://ansm.sante.fr/actualites/anticorps-monoclonaux-contre-la-covid-19-autorisation-en-acces-precoce-de-la-bitherapie-ronapreve-casirivimab-imdevimab-en-prophylaxie
2021
false
false
false
France
French
COVID-19
drug information
casirivimab and imdevimab drug combination
casirivimab
drug combinations
antibodies, monoclonal, humanized
imdevimab
Casirivimab/Imdevimab
risk assessment
COVID-19 aggravated
COVID-19
risk
infusions, intravenous
injections, subcutaneous
adult
adolescent
Pre-Exposure Prophylaxis
casirivimab and imdevimab drug combination
casirivimab and imdevimab
casirivimab and imdevimab drug combination
drug combinations
Product containing only casirivimab and imdevimab in parenteral dose form (medicinal product form)

---
https://sante.gouv.fr//IMG/pdf/anticorps_monoclonaux_parcourspds-bitherapie_curatif_pf2.pdf
https://sante.gouv.fr//IMG/pdf/dgs-urgent_85_anticorps_monoclonal_bitherapie.pdf
https://sante.gouv.fr//IMG/pdf/anticorps_monoclonaux_parcourspds-bitherapieroche_prophylaxie_pf1.pdf
2021
false
false
false
France
casirivimab and imdevimab drug combination
guideline
COVID-19
Product containing only casirivimab and imdevimab in parenteral dose form (medicinal product form)
health facilities
patients
casirivimab and imdevimab drug combination
snacks
indicators
casirivimab
Maladjustment
has patient
monoclonal antibody
indicators and reagents
prophylactic treatment, nos
risk
antibodies, monoclonal
Monoclonal antibodies
hazardous substances
traction
indication of
imdevimab
Monoclonal antibodies

---
https://ansm.sante.fr/actualites/covid-19-extension-de-lutilisation-de-la-bitherapie-danticorps-monoclonaux-casirivimab-imdevimab-chez-certains-patients-hospitalises
2021
false
false
false
France
French
casirivimab and imdevimab drug combination
casirivimab and imdevimab
guidelines for drug use
summary of product characteristics
package leaflet
Product containing only casirivimab and imdevimab in parenteral dose form (medicinal product form)
COVID-19
COVID-19
immunocompromised host
casirivimab and imdevimab drug combination
casirivimab
imdevimab
adult
aged
adolescent
Pre-Exposure Prophylaxis
Post-Exposure prophylaxis
inpatients
casirivimab and imdevimab drug combination
drug combinations
antibodies, monoclonal, humanized
coronavirus infections

---
https://www.has-sante.fr/jcms/p_3281544/fr/ronapreve-casirivimab-imdevimab-prophylaxie-pre-exposition-de-l-infection-a-sars-cov-2
https://has-sante.fr/jcms/p_3291779/fr/decision-n-2021-0259/dc/sem-du-7-octobre-2021-du-college-de-la-haute-autorite-de-sante-portant-autorisation-d-acces-precoce-de-la-specialite-ronapreve
2021
false
false
false
France
French
casirivimab and imdevimab drug combination
casirivimab and imdevimab
drug information
package leaflet
summary of product characteristics
guidelines for drug use
Product containing only casirivimab and imdevimab in parenteral dose form (medicinal product form)
casirivimab and imdevimab drug combination
drug combinations
antibodies, monoclonal, humanized
casirivimab and imdevimab drug combination
treatment outcome
drug approval
Pre-Exposure Prophylaxis
COVID-19
injections, subcutaneous
infusions, intravenous
casirivimab
imdevimab
adult
adolescent

---
https://www.ema.europa.eu/en/medicines/human/EPAR/ronapreve
2021
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
drug combinations
casirivimab
casirivimab
Casirivimab/Imdevimab
imdevimab
imdevimab
adult
adolescent
COVID-19
COVID-19
infusions, intravenous
injections, subcutaneous
spike glycoprotein, coronavirus
product surveillance, postmarketing
Post-Exposure prophylaxis
Pre-Exposure Prophylaxis
pregnancy
breast feeding
Product containing only casirivimab and imdevimab in parenteral dose form (medicinal product form)
casirivimab and imdevimab drug combination
casirivimab and imdevimab

---
https://ansm.sante.fr/tableau-atu-rtu/casirivimab-imdevimab-120-mg-ml-solution-a-diluer-pour-perfusion-intraveineuse-ou-solution-pour-injection-sous-cutanee
2021
false
false
false
France
French
guidelines for drug use
antibodies, monoclonal, humanized
Casirivimab/Imdevimab
Casirivimab
infusions, intravenous
drug combinations
Imdevimab
summary of product characteristics
package leaflet
adult
aged
COVID-19
imdevimab
casirivimab and imdevimab drug combination
casirivimab
casirivimab and imdevimab drug combination
casirivimab and imdevimab
Pre-Exposure Prophylaxis
Product containing only casirivimab and imdevimab in parenteral dose form (medicinal product form)
Post-Exposure prophylaxis
casirivimab and imdevimab drug combination

---
https://www.ansm.sante.fr/actualites/anticorps-monoclonaux-lansm-permet-lutilisation-en-acces-precoce-de-deux-bitherapies-contre-la-covid-19
2021
false
false
false
France
French
scientific and technical information
drug information
antibodies, monoclonal
adult
Casirivimab/Imdevimab
Casirivimab
Imdevimab
Anti-spike Protein SARS-CoV-2 Monoclonal Antibody
Bamlanivimab
Etesevimab
aged
spike glycoprotein, coronavirus
france
drug monitoring
risk
drug combinations
casirivimab and imdevimab drug combination
COVID-19
COVID-19
casirivimab
imdevimab
casirivimab and imdevimab
drug combinations
antibodies, monoclonal, humanized
Product containing only casirivimab and imdevimab in parenteral dose form (medicinal product form)
casirivimab and imdevimab drug combination

---
https://www.has-sante.fr/jcms/p_3281625/fr/ronapreve-casirivimab-imdevimab-prophylaxie-post-exposition-de-l-infection-a-sars-cov-2
https://has-sante.fr/jcms/p_3291779/fr/decision-n-2021-0259/dc/sem-du-7-octobre-2021-du-college-de-la-haute-autorite-de-sante-portant-autorisation-d-acces-precoce-de-la-specialite-ronapreve
2021
false
false
false
France
casirivimab and imdevimab drug combination
casirivimab and imdevimab
evaluation of the transparency committee
casirivimab
imdevimab
casirivimab and imdevimab drug combination
drug combinations
antibodies, monoclonal, humanized
Product containing only casirivimab and imdevimab in parenteral dose form (medicinal product form)
infusions, intravenous
injections, subcutaneous
Post-Exposure prophylaxis
COVID-19
treatment outcome
adult
adolescent
drug approval
france

---